Shareholders of ImmunityBio, Inc. (NASDAQ:IBRX) will be pleased this week, given that the stock price is up 15% to US$8.51 following its latest first-quarter results. It was a pretty bad result overall; while revenues were in line with expectations at US$44m, statutory losses exploded to US$0.62 per share. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.

After the latest results, the four analysts covering ImmunityBio are now predicting revenues of US$229.8m in 2026. If met, this would reflect a huge 63% improvement in revenue compared to the last 12 months. Losses are expected to increase slightly, to US$0.83 per share. Before this earnings announcement, the analysts had been modelling revenues of US$218.7m and losses of US$0.26 per share in 2026. So it's pretty clear the analysts have mixed opinions on ImmunityBio even after this update; although they upped their revenue numbers, it came at the cost of a regrettable increase in per-share losses.

The consensus price target stayed unchanged at US$15.25, seeming to suggest that higher forecast losses are not expected to have a long term impact on the valuation. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. Currently, the most bullish analyst values ImmunityBio at US$22.00 per share, while the most bearish prices it at US$12.00. Note the wide gap in analyst price targets? This implies to us that there is a fairly broad range of possible scenarios for the underlying business.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. We can infer from the latest estimates that forecasts expect a continuation of ImmunityBio'shistorical trends, as the 92% annualised revenue growth to the end of 2026 is roughly in line with the 90% annual growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 22% annually. So it's pretty clear that ImmunityBio is forecast to grow substantially faster than its industry.

The Bottom Line

The most important thing to take away is that the analysts increased their loss per share estimates for next year. Pleasantly, they also upgraded their revenue estimates, and their forecasts suggest the business is expected to grow faster than the wider industry. The consensus price target held steady at US$15.25, with the latest estimates not enough to have an impact on their price targets.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. At Simply Wall St, we have a full range of analyst estimates for ImmunityBio going out to 2028, and you can see them free on our platform here..

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.